 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Kezar Life Sciences, Inc. Nasdaq: KZR, a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis PM and dermatomyositis DM completed the target enrollment of 24 subjects. PRESIDIO is a Phase 2 randomized, placebo-controlled, crosso 